Shares of Peregrine Pharmaceuticals soared up to 33% intraday before closing with a still impressive 19% gain, thanks to the announcement that the FDA green-lit bavituximab's phase 3 non-small-cell lung cancer trial.
In this video, health-care analyst David Williamson discusses whether the FDA decision justified this type of bullish enthusiasm and whether Peregrine is doing right by investors in starting this trial, given bavituximab's phase 2 troubles.
Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.